Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.67 USD | +1.14% | -1.84% | -61.16% |
May. 30 | SAB Biotherapeutics, Inc. Announces Change of Chief Financial Officer | CI |
May. 21 | FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-61.16% | 24.63M | |
+15.55% | 121B | |
+12.66% | 107B | |
-2.53% | 24.82B | |
+0.99% | 22.48B | |
-9.35% | 18.32B | |
-42.28% | 16.33B | |
-18.92% | 15.31B | |
+6.19% | 14.08B | |
+28.83% | 11.74B |
- Stock Market
- Equities
- SABS Stock
- News SAB Biotherapeutics, Inc.
- Northland Securities Adjusts SAB Biotherapeutics PT to $21 From $18, Maintains Outperform Rating